Skip to main content
NIH funding notice RFA-AG-23-005

Health Equity and the Cost of Novel Treatments for Alzheimers Disease and Related Dementias (R61/R33 Clinical Trial Not Allowed)

Closed on July 1, 2022.

Posted
February 17, 2022
Close date
July 1, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $642,234 in first-year total cost, median $321,117.

Most frequent study sections

  1. Special Emphasis Panel[ZAG1 ZIJ-R (J2)]2

Most frequent institutions

  1. UNIVERSITY OF SOUTHERN CALIFORNIA1
  2. VIRGINIA COMMONWEALTH UNIVERSITY1
Competing awards under RFA-AG-23-005 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Measuring the Impact of the Value Flower and Unobserved Heterogeneity on the Cost Effectiveness and Use of Novel Treatments for Alzheimer's Disease and Related Dementias1R61AG081939-01ATHERLY, ADAM JVIRGINIA COMMONWEALTH UNIVERSITY, VA$321,225ZAG1
2023Use and Impact of Novel and Repurposed Therapeutics for Alzheimer's Disease and Related Dementia in Diverse Populations1R61AG081811-01BENNETT, DAVID ALANZISSIMOPOULOS, JULIE MUNIVERSITY OF SOUTHERN CALIFORNIA, CA$321,009ZAG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.